Bone and Renal Safety of Switching to Rilpivirine / Emtricitabine / Tenofovir Alafenamide (RPV/FTC/TAF) from Single-Tablet Regimens (STRs) Containing Efavirenz / Emtricitabine / Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) or Rilpivirine / Emtricitabine / Tenofovir Disoproxil Gumarate (RPV/FTC/TDF): Week 48 Subgroup Analysis in Patients at Risk of or with Comorbidities
EACS poster - ODE Switch In-depth Safety analysis at W48
